Key result
The Brief Executive-function Assessment Tool (BEAT) demonstrated 87% sensitivity, 71% specificity, and 99% negative predictive value for detecting cognitive impairment in individuals with SUD.
Why the study?
No screening measure had been developed specifically to detect cognitive impairment in individuals receiving substance use disorder treatment.
Does the Brief Executive-function Assessment Tool (BEAT) accurately screen for cognitive impairment in individuals with substance use disorder?
Observational (n=646)
Does the Brief Executive-function Assessment Tool (BEAT) accurately screen for cognitive impairment in individuals with substance use disorder?
The BEAT is a reliable and valid screening measure for executive function impairment in individuals with substance use disorder, featuring high sensitivity and a low rate of false negatives.
Answers are grounded in this paper and cite their sources.
BEAT validation in SUD populations remains preliminary; prospective trials needed before screening adoption.
Accurate screening for cognitive impairment in alcohol and other drug (AOD) services would help to identify individuals who may need supports to obtain the greatest benefit from substance use disorder (SUD) treatment. At present there is no screening measure that has been developed specifically to detect cognitive impairment in a SUD population. This study examines the psychometric properties of the Brief Executive-function Assessment Tool (BEAT), which was specifically designed for this purpose. This study involving 501 individuals with SUD and 145 normal control participants established internal consistency (n = 646; 0.734), interrater (n = 60; 0.994), and test–retest reliability (n = 177; 0.845), and construct (all correlations p ≤ 0.05), and criterion (n = 467; ANCOVA p < 0.001) validity. Test operating characteristics (n = 500; 87% sensitivity, 71% specificity, 21% PPP, and 99% NPP) were also established relative to an independent criterion variable made up of three established performance-based neuropsychological tests. Findings support the reliability and validity of the BEAT as a screening measure of executive function impairment with high sensitivity and a low rate of false negatives.
No takes yet. Share an insight, caveat, or question.
Berry et al. (2021) conducted an observational in Substance use disorder (n=646). Brief Executive-function Assessment Tool (BEAT) vs. Established performance-based neuropsychological tests was evaluated on Test operating characteristics for detecting cognitive impairment (87% sensitivity, 71% specificity, 21% PPP, 99% NPP). The Brief Executive-function Assessment Tool (BEAT) demonstrated 87% sensitivity, 71% specificity, and 99% negative predictive value for detecting cognitive impairment in individuals with SUD.
Synapse has enriched 10 related papers. Consider them for comparative context: